Report Highlights

Keratoacanthoma Care in the United States: Market Overview

The U.S. keratoacanthoma market is valued at USD 486 million in 2024 across diagnostics, excision, Mohs micrographic surgery, and topical or intralesional therapy. Its structure is fragmented: dermatology practices perform most excisions, while hospital outpatient departments and ambulatory surgery centers absorb complex Mohs cases. Keratoacanthoma is classified by the FDA and CMS within broader cutaneous squamous cell carcinoma and keratinocyte codes, so it has no standalone label or payment category.

Government has been the dominant force in shaping reimbursement and evidence standards, through CMS fee schedules, Medicare national coverage policy, and National Cancer Institute funding for keratinocyte carcinoma research. Private sector innovation has led in product development, with Regeneron and Merck driving immune checkpoint use in advanced cutaneous squamous cell carcinoma, and Viatris supplying imiquimod and Bausch Health supplying fluorouracil, both used off-label for keratoacanthoma.

Policy-Driven Growth in U.S. Keratoacanthoma Care

Three mechanisms drive demand. First, Section 11001 of the Inflation Reduction Act of 2022 (Public Law 117-169) creates Medicare Part B drug price negotiation from 2028, which shifts manufacturer incentives toward branded immunotherapies for advanced cutaneous squamous cell carcinoma. Second, Medicare Physician Fee Schedule payment for Mohs codes 17311 through 17315 sustains procedure volume, because Mohs remains the reference standard for high-risk keratinocyte lesions.

Third, the Surveillance, Epidemiology, and End Results program run by the National Cancer Institute, together with the National Program of Cancer Registries administered by the CDC, produces incidence data that underpins FDA label-expansion submissions and payer coverage reviews. Registry data documents rising non-melanoma skin cancer incidence, which surgical groups cite to justify Mohs capacity investment, translating epidemiological growth into procedure and drug demand.

Regulatory Barriers and Compliance Costs

Drug development faces FDA oversight under the Federal Food, Drug, and Cosmetic Act and 21 CFR Part 314, with new drug applications requiring phase III evidence in keratinocyte carcinomas. Keratoacanthoma trials are small because incidence is low, so sponsors must seek indication expansion through cutaneous squamous cell carcinoma submissions, adding an estimated 24 to 36 months and USD 150 million to USD 300 million in development costs per program.

Diagnostic barriers sit with CMS under the Clinical Laboratory Improvement Amendments of 1988, which require certification for dermatopathology laboratories processing biopsies. The March 2025 federal court decision that vacated FDA's laboratory developed test rule left pathology services under CLIA alone, leaving labs to bear validation costs of roughly USD 40,000 to USD 80,000 per new assay, while California laboratory licensure under Health and Safety Code Section 1200 adds separate state approvals.

Policy-Created Opportunities in U.S. Keratoacanthoma Care

The Part D redesign under the Inflation Reduction Act, effective 2025, caps annual out-of-pocket spending at USD 2,000 for Medicare beneficiaries, which shifts demand toward generic fluorouracil and imiquimod for lesion management. Manufacturers that secure generic or authorized-generic supply of these agents, such as Viatris and Bausch Health, capture volume as Medicare patients adopt longer treatment courses.

Regulatory incentives for novel therapies create a second opening. Orphan drug designation under the Orphan Drug Act (21 U.S.C. Section 360bb) grants seven years of market exclusivity, and the federal orphan drug tax credit under IRC Section 45C covers 25 percent of qualified clinical testing expenses. Sponsors developing keratoacanthoma-specific intralesional agents can pursue this designation because the condition falls within the under-200,000-patient threshold.

Market at a Glance

Leading Market Participants

• Regeneron Pharmaceuticals
• Merck & Co.
• Viatris
• Bausch Health Companies
• Galderma
• Sun Pharmaceutical Industries
• Almirall
• Sensus Healthcare
• Castle Biosciences
• Bristol Myers Squibb

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Chapter 9) and the Public Health Service Act, administered by the FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Key compliance requirements include investigational new drug filings under 21 CFR Part 312, marketing approvals under Part 314 for small molecules and Part 601 for biologics, and current good manufacturing practice under 21 CFR Parts 210 and 211.

Upcoming changes include Medicare drug price negotiation, under which CMS selects Part B drugs by February 1, 2026, with negotiated prices effective January 1, 2028. Compared with peers, the U.S. framework is more permissive for Mohs surgery than Canada's provincial coverage limits and more costly than the UK's NICE pathway, where dermatology drugs face cost-effectiveness thresholds of GBP 20,000 to GBP 30,000 per QALY.

Long-Term Policy Outlook for U.S. Keratoacanthoma Care

By 2032, CMS negotiated prices will cover Part B immunotherapies, pressuring branded cemiplimab and pembrolizumab pricing and redirecting spend toward procedural care. The CY2026 Medicare Physician Fee Schedule applies a negative 2.5 percent efficiency adjustment to non-time-based services, which will compress procedural margins for Mohs and excision codes through 2032.

Dermatopathology reimbursement will tighten as CMS updates the Clinical Laboratory Fee Schedule under PAMA reporting, compressing lab margins and accelerating consolidation among regional pathology groups. Market participants that align with CLIA-certified networks and Mohs centers before 2030 will hold the procedural volume by 2032.